Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcium Lactate→

Calcium Lactate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
814-80-2
Molecular formula
C6H10CaO6
Molecular weight
218.22 g/mol
Drug class
Inorganic calcium saltoral calcium supplement
Mechanism of action
Dissociates in the gastrointestinal tract to provide calcium ions for intestinal absorption and maintenance of normal extracellular calcium, bone mineralisation and neuromuscular function.
Indications / reported uses
  • Prevention and treatment of inadequate calcium intake and calcium deficiency as an oral supplement; use in clinically significant hypocalcaemia depends on the formulation and local product authorisation

Sources: NIH Office of Dietary Supplements — Calcium fact sheet · PubChem — Calcium lactate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Calcium Lactate Environmental Risk Assessment (ERA) (the Calcium Lactate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.